中国第二款，即科兴疫苗，土耳其第三期83.5%。10 weeks 内可生产出针对变异病毒的产品。2021.6.1 WHO批准

支持也好反对也好，中国疫苗应该没有大问题，那么多国家都有自己的科学家，哪个不比CFCers信息多，专业知识强？
 
Screenshot_20210104_072307.jpg
 
中国的elderly的定义可能不一样，50岁可能就是老人了，至少招聘的时候是这个标准。

报告里用elderly比较含糊，应该用数字年龄。
 
贵圈 说:
等着看数字和report。是100%有效无害吗？
点击展开...
除了毒药，你长这么大，见过世界上存在百分百有效无害的药吗？ 感冒药都不敢说百分百治愈率没有副作用
 
我没有啊，
thundebay 说:
除了毒药，你长这么大，见过世界上存在百分百有效无害的药吗？ 感冒药都不敢说百分百治愈率没有副作用
点击展开...
 

巴西叛变了，直接把中国科兴2021年灭活疫苗全部买断。​


来源: 中航科工六院 于 2021-01-08 07:36:30

巴西卫生部长帕洛祖（Eduardo Pazuello）1月7日宣布，巴西联邦

政府与圣保罗州布坦坦研究所（Butantan Institute）签署协议购买中国科兴生物本年生产的所有新冠疫苗，总数达1亿剂。研究所已经向巴西卫生监督局申请科兴疫苗的紧急使用许可，巴西最快于1月20日启动全国接种疫苗计划。

帕洛祖说，布坦坦研究所会在四月底前交付首批4600万剂科兴疫苗，其余5400万剂则会于本年内交付。巴西正面对新一波疫情，死亡人数累计达20万人。

在签署协议前夕，布坦坦研究所公布中国科兴疫苗第三阶段临床测试结果，轻度患者的有效率为78%。虽然这个数字较美国食药管理局批准使用的辉瑞和Modern疫苗为低（分别是90%及95% ），但布坦坦研究所指，科兴疫苗对重症患者的预防率为100%。

巴西总统博尔索纳罗（Bolsonaro）去年曾称，不会购买任何中国制造的新冠疫苗。卫生部长帕洛祖在记者会上表示，与科兴签订的合约将禁止巴西向辉瑞购买新冠疫苗。巴西当局目前也正洽商采购俄罗斯Sputnik-V新冠疫苗。

巴西叛变了，直接把中国科兴2021年灭活疫苗全部买断。 - 中航科工六院发表于 时事述评 - 论坛 | 文学城

bbs.wenxuecity.com bbs.wenxuecity.com
 
1月11日，印尼食品和药物监督管理局批准紧急使用中国科兴疫苗。这种由中国生物医药公司生产的疫苗正在印尼万隆进行第三期试验，有1600名志愿者参与了试验。印尼生物制药公司的负责人潘妮在雅加达介绍说，疫苗的有效性为65.3%。
 

Southeast Asia is embracing China’s Sinovac vaccine​


By Mary Hui
Reporter
January 13, 2021
In a livestream from the Indonesian presidential secretariat’s YouTube channel, the country’s leader Joko Widodo rolled up his sleeves to receive his shot of the Sinovac coronavirus vaccine, kicking off the nation’s mass inoculation campaign.

His vaccination comes just two days after Indonesia became the first country outside China to grant emergency use authorization to privately Chinese biotech firm Sinovac’s Covid-19 shot. Indonesia has already secured 330 million doses of the vaccine, and so far about 29 million doses have been delivered to the country.

Elsewhere in Southeast Asia, countries have also readily embraced the Sinovac, even as wildly different efficacy rates have been recorded for its vaccine. What was reported by Brazil’s public Butantan Institute, the country’s major vaccine provider, last week as a 78% efficacy rate was tampered by rumblings that it was actually less than 60% effective, before the institute sharply revised the total efficacy rate to 50.4% yesterday. Over 12,000 volunteers took part in those trials, the vaccine’s largest.

That’s much lower than the 91.25% and 65% efficacy rates Turkey and Indonesia had previously reported from separate small clinical trials, respectively. Limited data have been published from any of these trials, however, raising questions of transparency. The relatively low efficacy rate will “have implications for China’s vaccine diplomacy as well as its domestic vaccination campaign,” noted Yanzhong Huang, a senior fellow for global health at the Council on Foreign Relations in New York.

It may also complicate matters for the World Health Organization, which is currently assessing whether to add the Sinovac vaccine to its emergency-use listing.

“Because it is at the borderline of the WHO-imposed cutoff efficacy rate [of 50%], the WHO might find it not so easy to make the decision to pre-qualify the China-made vaccine because…it may raise doubts over whether the WHO made the decision to defer to the Chinese government’s request, so there’s the question of credibility and reputation at stake,” said Huang.

To be clear, a 50% efficacy, while not ideal, is still better than nothing. Antony Fauci, the US’s leading infectious disease expert, had last summer said that a 50% to 60% efficacy rate would be acceptable. For comparison, seasonal flu vaccines are typically 40% to 60% effective.
Florian Krammer, an immunologist at the Icahn School of Medicine at Mount Sinai in New York, gave the following verdict on Sinovac in light of the latest results out of Brazil: “Likely still useful. But not really my first choice…”

So far, the conflicting data does not appear to have deterred Southeast Asian nations from placing large orders for the Sinovac vaccine.
The Philippines announced yesterday that its first ever batch of coronavirus vaccines will be from Sinovac, with the first 50,000 doses allotted for the country’s frontline medical workers and no other vaccines from other drugmakers expected to be available until at least June.

Thailand is currently processing applications from Sinovac and AstraZeneca to register their vaccines for use in the country. Though the overwhelming bulk of Thailand’s vaccine orders have been for AstraZeneca’s, Sinovac’s is expected to be ready next month, while the latter’s won’t be ready until May. Malaysia has also procured 14 million Sinovac doses, in addition to 25 million shots from Pfizer-BioNTech and 6.4 million doses from AstraZeneca.
 
您必须登录或注册才可回复。
后退
顶部